WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative nanotechnology-based ophthalmic products leveraging the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of a Phase 2 clinical trial (KPI-121-C-004) to evaluate KP-121, the company’s loteprednol etabonate MPP (“LE-MPP”) drug product, in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME). In addition, Kala has initiated a Phase 2 clinical trial (KPI-121-C-003) of LE-MPP in subjects with meibomian gland disease (MGD).
Help employers find you! Check out all the jobs and post your resume.
